From anti-proliferation to immunomodulation: engineering next-generation cardiovascular biomaterials

Area of Science:

• Biomaterials Science
• Immunology
• Cardiovascular Engineering

Background:

• Cardiovascular devices like stents and valves face limitations due to chronic inflammation and poor tissue integration, hindering long-term success.
• Current drug-eluting devices often use broad anti-proliferative agents that impede healing, failing to address the root causes of device failure.
• Dysregulated inflammation is increasingly recognized as a key factor in the suboptimal performance of cardiovascular implants.

Purpose of the Study:

• To review emerging selective immunomodulatory strategies for cardiovascular devices.
• To evaluate novel anti-inflammatory approaches and targeted delivery platforms.
• To identify translational challenges and propose integration pathways for immunomodulatory device design.

Main Methods:

• Review of current literature on anti-inflammatory strategies and biomaterials for cardiovascular devices.
• Analysis of dual-drug systems, multimodal agents, and various delivery platforms (polymeric coatings, hydrogels, nanoparticles).
• Evaluation of the potential of immunomodulatory approaches to promote vascular regeneration.

Main Results:

• Selective immunomodulation offers a promising alternative to broad anti-proliferative agents by targeting pathological inflammation.
• Advanced delivery systems, including polymeric coatings, hydrogels, and nanoparticles, show potential for targeted drug delivery.
• Dual-drug and multimodal systems can offer synergistic therapeutic effects for enhanced device performance.

Conclusions:

• Integrating selective immunomodulatory strategies into cardiovascular device design is crucial for overcoming limitations of current technologies.
• Targeted delivery platforms are essential for maximizing the efficacy of anti-inflammatory agents while minimizing off-target effects.
• Addressing translational challenges is key to developing clinically scalable immunomodulatory cardiovascular devices for improved patient outcomes.